Q-omics provides the consensus-scored FXYD4 profile across patient tissues and cancer cell-line models. FXYD4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, FXYD4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FXYD4 RNA expression shows 11,179 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ESCA, KIRC, and TGCT as cancer lineages where FXYD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FXYD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FXYD4 survival associations across molecular data types. FXYD4 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FXYD4 RNA expression–survival associations across cancer types. High FXYD4 expression shows unfavorable associations in ESCA, UVM, LUSC, BRCA, KIRC and THCA. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for FXYD4 RNA expression.
This table summarizes FXYD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FXYD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FXYD4 shows lower tumor expression in KIRC, KIRP, KICH and LUSC and higher tumor expression in COAD and UCEC. The KIRC box plot shows higher FXYD4 RNA expression in normal versus tumor tissue (log2 FC = −8.492, t-test p < 0.001).
This table shows molecular features associated with FXYD4 in patient tissues and cancer cell lines. In patient samples, FXYD4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FXYD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
